? PLANNING AND EVALUATION The Lurie Cancer Center (LCC) has a well-developed system for planning and evaluation. As new LCC Director, Dr. Platanias established a new Senior Leadership team, with well-defined roles and responsibilities: (1) Maha Hussain, M.D. was appointed as Deputy Director, (2) Kathleen Green, Ph.D. as Associate Director for Basic Sciences Research, (3) Massimo Cristofanilli, M.D., as Associate Director for Translational Research, (4) Milan Mrksich, Ph.D. as Associate Director for Shared Resources, (5) Aleksandar Zafirovski, M.B.A., as Associate Director for Administration and (6) Jeffrey Wayne, M.D. as Associate Director for Clinical Operations. Among the Associate Directors continuing in their positions are (1) David Cella, Ph.D., for Cancer Prevention and Control Research, (2) John Crispino, Ph.D., for Education and Training and (3) Alexis Thompson, M.D., for Equity and Minority Health. This team works collectively as the Executive Committee (EC), which meets every two weeks and is the primary decision making body that sets the overall strategic direction of the Center. The EC provides direction in matters relevant to LCC operations, management, and policy and oversees all research activities. It also sets budgetary and fiscal priorities and reviews LCC membership. CCSG support is requested for all Senior Leadership positions except the position of Associate Director for Clinical Operations. In addition to the EC, there are several other governance structures that provide the primary means by which the LCC conducts planning and evaluation on an ongoing basis. These are the Scientific Research Council (SCRC), the Clinical Cancer Center Executive Council (CCCEC), the Program Leaders Committee (PLC) and the Internal and External Advisory Boards. The SCRC includes the Associate Directors and all Program and Shared Resource leaders/directors, and meets quarterly to review initiatives and provide input for research programs, shared resources and training/education. The PLC, a new committee established by Dr. Platanias, meets monthly to discuss joint initiatives within and between programs and provides important input to the EC. The External Advisory Board (EAB) is comprised of recognized leaders in clinical, basic and population sciences, biostatistics and center administration, and meets at least annually to review all aspects of LCC operations and initiatives. After his appointment as Director, Dr. Platanias increased the number of EAB members and made several new EAB appointments with input from other senior leaders. Additional planning input is provided by retreats, other Center advisory committees, surveys and ad hoc reviews. With careful planning and critical input from the different advisory groups, the Director initiated a new five-year strategic planning process, reorganized center research program membership, and created working groups to continue improving oversight and governance. These coordinated teams provide critical advice and guidance, ensuring that the LCC most effectively sets priorities and pursues objectives that promote its mission. CCSG support is requested for the activities of the EAB, which plays an essential role in the evaluation of the LCC?s programs and organization.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Hong, Bong Jin; Iscen, Aysenur; Chipre, Anthony J et al. (2018) Highly Stable, Ultrasmall Polymer-Grafted Nanobins (usPGNs) with Stimuli-Responsive Capability. J Phys Chem Lett 9:1133-1139
Smith, Erica D; Garza-Gongora, Arturo G; MacQuarrie, Kyle L et al. (2018) Interstitial telomeric loops and implications of the interaction between TRF2 and lamin A/C. Differentiation 102:19-26
Hsiao, Hsi-Min; Fernandez, Ramiro; Tanaka, Satona et al. (2018) Spleen-derived classical monocytes mediate lung ischemia-reperfusion injury through IL-1?. J Clin Invest 128:2833-2847
Mehta, Amol; Awah, Chidiebere U; Sonabend, Adam M (2018) Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy. Front Neurol 9:459
Brown, Jessica H; Das, Prativa; DiVito, Michael D et al. (2018) Nanofibrous PLGA electrospun scaffolds modified with type I collagen influence hepatocyte function and support viability in vitro. Acta Biomater 73:217-227
Ntai, Ioanna; Fornelli, Luca; DeHart, Caroline J et al. (2018) Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk. Proc Natl Acad Sci U S A 115:4140-4145
Wiwatpanit, Teerawat; Remis, Natalie N; Ahmad, Aisha et al. (2018) Codeficiency of Lysosomal Mucolipins 3 and 1 in Cochlear Hair Cells Diminishes Outer Hair Cell Longevity and Accelerates Age-Related Hearing Loss. J Neurosci 38:3177-3189
Malik, Neha; Iyamu, Iredia D; Scheidt, Karl A et al. (2018) Synthesis of a novel fused pyrrolodiazepine-based library with anti-cancer activity. Tetrahedron Lett 59:1513-1516
Wong, Yvette C; Ysselstein, Daniel; Krainc, Dimitri (2018) Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis. Nature 554:382-386
Ladomersky, Erik; Zhai, Lijie; Lenzen, Alicia et al. (2018) IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res 24:2559-2573

Showing the most recent 10 out of 1972 publications